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a b s t r a c t
Objectives: To analyse the inﬂuence of IFNa on TNFa production by human peripheral blood mononu-
clear cells (PBMCs), as well as the possible interference of this cytokine on the effect of antimalarial drugs,
TNFa regulators widely used in the treatment of systemic lupus erythematosus (SLE).
Methods: PBMCs, monocytes or T cells were treated with IFNa alone or simultaneously to cellular stimuli
as well as in the presence or absence of chloroquine. Supernatants from such cultures were collected to
quantify TNFa by ELISA. TNFa and STAT4 expression in cultured cells were analysed by intracellular ﬂow
cytometry. In addition, STAT4 gene expression and serum levels of TNFa and IFNa were quantiﬁed in 53
SLE patients and 45 controls.
Results: IFNa alone did not modify signiﬁcantly TNFa production, but an increase was observed in stim-
ulated PBMC. Further analyses showed that monocytes were the cellular population responsible for this
effect. In addition, IFNa treatment increased STAT4 in stimulated monocytes, suggesting that TNFa
upregulation could be mediated by STAT4. On the other hand, the analysis of the antimalarial effect
showed that chloroquine was able to inhibit in vitro the expression of TNFa and STAT4 enhanced by IFNa.
In antimalarial-treated SLE patients, however, only those with high IFNa serum levels presented lower
expression of STAT4.
Conclusions: IFNa treatment enhances the induction of TNFa and STAT4 in stimulated monocytes, an
effect inhibited in vitro by chloroquine treatment. However, the consequence of antimalarial treatment
on SLE patients could be different depending on their IFNa serum levels.
 2014 Elsevier Ltd. All rights reserved.
1. Introduction
Interferon alpha (IFNa) is a cytokine of the type I IFN family
with a wide range of effects upon the immune system, including
a potent host-protective antiviral response. In fact, IFNa can induce
the activation, differentiation and maturation of monocytes into
dendritic cells (DCs), increasing the expression of MHC and
co-stimulatory molecules [1,2]. In addition, it can produce B cell
activation, differentiation and antibody production [3]. These
immune-stimulant functions place IFNa in a critical position
bridging innate and adaptive immune responses, and suggest that
IFNa could be important in the pathogenesis of autoimmunity. The
pivotal role of IFNa in the pathogenesis of systemic lupus
erythematosus (SLE) and other autoimmune diseases [4] is well
established, since the majority of patients present increased pro-
duction of type I IFN as well as IFNa-induced genes [5,6]. More-
over, Rönnblom and Alm demonstrated that immunocomplexes
containing nucleic acids, characteristic of SLE serum, could trigger
the production of high levels of IFNa [7] by plasmacytoid DCs
through their interaction with the Toll-like receptor (TLR)-7 and
TLR-9 [8,9].
The signal transducer and activator of transcription 4 (STAT4) is
one of the gene products involved in the IFNa signaling, and it can
be activated and phosphorylated upon ligation of the type I IFN
receptor by IFNa in monocytes, macrophages, DCs, and T lympho-
cytes [10]. Following activation, human STAT4 binds to regulatory
regions of several genes to induce proinﬂammatory cell-mediated
immunity [11]. Interestingly, STAT4 variants are associated with
susceptibility to SLE [12,13] and the STAT4 risk allele is associated
with nephritis and antibodies to double-stranded DNA, two clinical
features linked to the severity and activity of the disease [14].
Antimalarial drugs (hydroxychloroquine, chloroquine, and
quinacrine) have been used for a long time as disease modifying
antirheumatic agents in the treatment of SLE and other
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autoimmune diseases and they are still widely prescribed. It has
been described that antimalarials prevent lupus ﬂares and increase
long-term survival of SLE patients [15,16], probably due to their
ability to downregulate the production of TNFa and other
proinﬂammatory cytokines, demonstrated in vitro by stimulated
human monocytes [17–19], and in SLE patients [20,21]. Although
the mechanisms for antimalarials are not completely known, it
has been described they may block the TLR interaction with nucleic
acid ligands by altering lysosomal acidiﬁcation and disrupting
endosomal maturation [22], constituting an interesting therapy
for the IFNa blockade, which could prevent the activation of proin-
ﬂammatory pathways. In fact, it has been previously observed a
notable positive correlation between serum levels of IFNa and
TNFa [23,24], both cytokines considered essential elements in
the etiopathology of the SLE [5,25].
In view of all this evidence, in the present study we investigated
the possible involvement of IFNa in the TNFa induction and the
STAT4 upregulation, as well as the effect of the antimalarial treat-
ment both in vitro and in vivo.
2. Material and methods
2.1. Cellular isolation
Human peripheral blood mononuclear cells (PBMCs) were
obtained from standard buffy-coat preparations from routine
healthy donors (Asturian Blood Transfusion Center, Oviedo, Spain)
by centrifugation over Ficoll–Hypaque gradients (Lymphoprep,
Nycomed, Norway). Monocytes and T lymphocytes were isolated
by means of a Percoll gradient as previously described [2,26]. The
monocyte-cell population obtained from the gradient was approx-
imately 85% surface CD14+, while T cells were more than 95% CD3+,
as determined by ﬂow cytometry. Independent experiments were
performed with cells from different individuals. All blood donors
(the number is speciﬁed in each ﬁgure legend) were healthy adult
volunteers between 18 and 60 years old without any pathology or
treatment. Approval for this study was obtained from the Regional
Ethics Committee for Clinical Investigation.
2.2. Culture conditions
PBMCs, monocytes and T lymphocytes were incubated at
2  106 cells in the presence of phytohemaglutinin (PHA, 2.5 lg/
ml), lipopolysaccharide (LPS, 1 lg/ml), chloroquine (30 lM), re-
combinant human IFNa2b (Intron-A, 1000 U/ml), or their combina-
tions, in RPMI 1640 medium containing 2 mM L-glutamine and
25 mM Hepes (Bio Whitaker, Belgium) supplemented with 10%
heat-inactivated foetal calf serum and the antibiotics streptomycin
and ampicillin (100 g/ml) in 24-well ﬂat bottomed plates, at 37 C
in 5% CO2.
IFNa was obtained from Schering-Plough (Canada) in vials con-
taining 107 International Units (IU) that were dissolved in phos-
phate-buffered saline (PBS). LPS, PHA and chloroquine was
provided by Sigma Chemical Co. (USA) and dissolved in culture
medium.
2.3. Cytokine quantiﬁcation
Culture supernatants and serum samples were collected and
maintained at 80 C until cytokine determination. TNFa levels
were determined by an in-house ELISA as previously described
[20,23]. IFNa serum levels were quantiﬁed by ELISA (PBL Biomed-
ical, USA) following the manufacturer’s instructions. This assay has
been previously validated in 30 SLE patients and 8 healthy controls
by the positive correlations observed between the amount of IFNa
detected in the serum and the expression of IFNa-inducible genes
in peripheral blood cells (Supplementary Table 1). The lower limit
of detection was 7.5 pg/ml for TNFa and 3.12 pg/ml for IFNa.
2.4. Intracellular expression of TNFa and STAT4
Intracellular accumulation of TNFa and STAT4 was evaluated by
ﬂow cytometry in a FACSCanto II ﬂow cytometer (Becton Dickin-
son, BD Biosciences, CA). PBMCs were cultured in the presence
2 lM of monensin (Sigma) for the last 8 h. Then, cells were washed
and stained with the appropriate monoclonal antibody (MAb) or
with the corresponding isotype-matched conjugated irrelevant
MAb as a negative control. Extracellular staining of CD14 (Paciﬁc
Blue conjugated) was performed for 30 min at 4 C. After that, cells
were ﬁxed/permeabilized (Cytoﬁx/Cytoperm, BD Pharmingen) and
intracellularly stained with anti-TNFa (peridinin chlorophyll
protein [PerCP]-Cy5.5 conjugated) (eBiosciences Inc., CA) or
anti-STAT4 (ﬂuorescein isothiocyanate [FITC] conjugated) (BD
Pharmingen) following the manufacturer’s instructions. A mini-
mum of 10,000 viable monocytes, gated according to the CD14
expression, were acquired and analyzed using the FACSDiva soft-
ware 6.1.2 (BD Biosciences). Positive cells for each marker were
determined using the corresponding isotype-matched conjugated
irrelevant MAbs as negative control. The speciﬁc ﬂuorescence
intensity was quantiﬁed as the mean ﬂuorescence intensity (MFI)
calculated by subtracting the background of isotype matched con-
trol staining from the total ﬂuorescence.
2.5. STAT4 gene expression
Sample mRNA (poli-A+) was isolated from healthy cultured
monocytes or whole blood of SLE patients using the mRNA isola-
tion kit for blood/bone marrow (Boehringer Mannheim, USA). Re-
verse transcription was carried out by standard procedures. Real
time reverse transcriptase polymerase chain reaction (RT–PCR)
(LightCycler, Roche Diagnostics) was used to quantify STAT4 mRNA
by monitoring the ﬂuorescence emitted by SYBR Green I dye, using
an external standard (cDNA obtained from LPS stimulated periph-
eral blood mononuclear cells) to generate a calibration curve. b2-
microglobulin was used as the housekeeping gene, enabling the
determination of mRNA relative units. Primers employed were:
CACCTGCCACAT TGAGTCAACTA and TAAGACCACCAACGTACGA
for STAT4; and CCAGCAGAGAATGGAAAGTC and GATGCTGCTTA
CATGTCTCG for b2-microglobulin.
2.6. SLE patients
All patients included in the study (n = 53) were on the Asturian
SLE Register [27,28], were all Caucasian in origin, and fulﬁlled the
American College of Rheumatology (ACR) criteria for SLE [29].
Information on clinical features during the disease course was ob-
tained after a detailed review of clinical histories (Table 1). At the
time of sampling any patient had ﬂares of disease activity and they
were asked precise questions regarding the treatment received
over the previous 3 months. Sex and age-matched healthy controls
(n = 45 (38 women and 7 men); mean age ± SD: 43.36 ± 15.74)
were enlisted from the Asturian Blood Transfusion Center. In-
formed consent was obtained from all individuals prior to partici-
pation in the study, which was approved by the Regional Ethics
Committee for Clinical Investigation.
2.7. Statistical analysis
The Kolmogorov–Smirnov test was used to assess the normal
distribution of the data. Data from TNFa and STAT4 in vitro expres-
sion were represented by mean ± SD. Differences between culture
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conditions in the TNFa production in supernatants were assessed
by the Wilcoxon test for paired data, and differences in the TNFa
or STAT4 quantiﬁcation by ﬂow cytometry were tested by paired
T-test. Non-parametric testing was used to determine differences
between patient groups (Mann–Whitney U-test) and these data
were represented by median (interquartil range). GraphPad Prism
5 software (GraphPad Software) and SPSS 18.0 software package
(SPSS Inc.) were used for all determinations and a p < 0.05 was con-
sidered signiﬁcant.
3. Theory/calculation
In spite of the proposed cross-regulation between type I IFNs
and TNFa under homeostatic conditions, this equilibrium seems
to be loss in SLE, since both cytokines are usually increased in these
patients and probably involved in the etiopathology of the disease.
It is known that antimalarial drugs may downregulate proinﬂam-
matory mediators, but only are able to control the disease in sev-
eral patients. Thus, given the role of STAT4 in the induction of
proinﬂammatory mediators and cell-mediated immunity through
IFNa signaling in monocytes, analyzing the inﬂuence of IFNa levels
and the in vitro and in vivo effect of antimalarials on STAT4 and
TNFa expression should be of interest to detect a biomarker of
response to treatment.
4. Results
4.1. IFNa enhances TNFa expression in LPS-stimulated monocytes
To analyse the possible inﬂuence of IFNa on the TNFa produc-
tion, we ﬁrstly investigated the possible in vitro effect of IFNa on
the expression of TNFa by human immune cells. To this end,
freshly isolated PBMCs from healthy donors (n = 24) were incu-
bated during 48 h with IFNa alone or in combination with LPS or
PHA, and supernatants from such cultures were collected for the
quantiﬁcation of TNFa expression. Results suggest a faint effect
on TNFa secretion of the treatment with IFNa alone compared
with untreated cells (249.59 ± 425.15 vs 221.76 ± 254.15; n.s.).
However, the presence of IFNa signiﬁcantly increased TNFa secre-
tion in PBMCs stimulated with PHA (3658.99 ± 3897.62vs
3276.32 ± 3364.36, p = 0.03) and with LPS (3247.07 ± 2844.25 vs
2931.73 ± 3183.25, p = 0.01). Then, we examined separately in
monocytes and T cells the effect of IFNa at different times. As ex-
pected, IFNa as a single stimulant failed to promote signiﬁcant pro-
duction of TNFa in both cell types. However, the presence of IFNa
during monocyte stimulation with LPS increased notably TNFa
production, detecting a notable cytokine accumulation after 48 h
of culture (Fig. 1a). Conversely, IFNa addition to PHA-stimulated
T cells only showed a slight increase in TNFa expression (Fig. 1b).
Next, to conﬁrm this effect at the single cell level, we analyzed
IFNa induced TNFa production in LPS-stimulated monocytes by
intracellular ﬂow cytometry, thus avoiding possible effects of IFNa
on monocyte survival. To this end, PBMCs were incubated for 24 h
with IFNa alone, or in combination with LPS, and then TNFa
expression was analysed in CD14+ gated cells (Fig. 1c). In agree-
ment with the previous data, we observed an increase in the
amount of TNFa-producer cells in the presence of LPS (untreated:
4.89 ± 3.34 vs LPS: 19.32 ± 9.90, p = 0.01), that was signiﬁcantly en-
hanced in the presence of IFNa (29.78 ± 15.03, p = 0.03), an effect
also observed analyzing the MFI (LPS: 117.60 ± 67.86 vs LPS +
IFNa: 184.7 ± 99.72, p = 0.04).
4.2. Chloroquine inhibits IFNa-induced TNFa production and STAT4
expression
It is well known that antimalarial therapy inhibits the produc-
tion of TNFa and other proinﬂammatory cytokines [20,21], thus
we wanted to determine the inﬂuence of these drugs on the pro-
duction of TNFa induced by IFNa. As is shown in Fig. 2a, chloro-
quine treatment was able to reduce the TNFa secretion by
healthy cultured monocytes in all tested conditions. Also, the anal-
ysis of intracellular cytokine accumulation (Fig. 2b) showed that
chloroquine inhibits TNFa production by with LPS stimulated
monocytes in the presence of IFNa in a similar manner than in
the absence of this cytokine (LPS: 117.60 ± 67.86 vs LPS + CQ:
26.40 ± 23.04, p = 0.01; LPS + IFNa:184.7 ± 99.72 vs LPS + IF-
Na + CQ: 46.05 ± 20.94, p = 0.02).
Next, to determine the possible involvement of STAT4 in the
IFNa-induced TNFa production, we analysed STAT4 protein
expression in LPS-stimulated monocytes. To this end, cells were
cultured in the presence or absence of LPS, IFNa and chloroquine
for 24 h and then STAT4 expression was analyzed by intracellular
ﬂow cytometry (Fig. 3). As expected, IFNa treatment induced an in-
crease in the expression level of STAT4 by LPS-stimulated mono-
cytes (p = 0.03), however, the addition of chloroquine was able to
inhibit this IFNa-induced STAT4 expression (LPS: 189.10 ± 120.00
vs LPS + CQ: 78.88 ± 34.68, p = 0.03; LPS + IFNa: 262.81 ± 171.60
vs LPS + IFNa + CQ: 96.35 ± 89.65, p = 0.03). Furthermore, this
inhibitory effect of chloroquine on the IFNa-induced STAT4 levels
in LPS-stimulated monocytes was conﬁrmed at transcriptional le-
vel quantifying STAT4 gene expression by real time RT–PCR
(LPS + IFNa: 13.92 ± 5.65 vs LPS + IFNa + CQ: 7.53 ± 5.66, p = 0.01).
4.3. Circulating levels of IFNa affect the STAT4 expression in SLE
patients treated with antimalarials
Given the chloroquine ability to inhibit in vitro the expression of
STAT4 enhanced by IFNa, in an attempt to evaluate this effect
in vivo, we studied STAT4 gene expression and TNFa serum levels
in 53 SLE patients with (n = 29) and without (n = 24) antimalarial
therapy and presenting different IFNa serum levels. As we
have previously reported [23], serum levels of IFNa (18.11
Table 1
Demographic and clinical features of SLE patients.
Total SLE patients 53
Sex (female/male) (n) 50/3
Age at diagnosis, years (mean ± SD) 29.47 ± 11.60
Disease duration, years (mean ± SD) 15.19 ± 11.29
Clinical manifestations, n (%)
Malar rash 28 (52.8)
Discoid lesions 13 (24.5)
Photosensitivity 30 (56.6)
Oral ulcers 23 (43.4)
Arthritis 43 (81.1)
Serositis 12 (26.6)
Renal disorder 14 (26.4)
Neurologicaldisorder 4 (7.5)
Haematologicaldisorder 31 (58.5)
Autoantibodies, n (%)
ANAs 53 (100.0)
Anti-dsDNA/titer, U/ml (mean ± SD) 38 (71.7)/25.11 ± 42.09
Anti-SSa 22 (14.5)
Anti-SSb 12 (22.6)
Anti-Sm 4 (7.5)
Treatment, n (%)
None or NSAIDs 10 (18.9)
Antimalarial drugs 29 (54.7)
Glucocorticoids/Dose, mg/day (mean ± SD) 28 (52.8)/8.14 ± 6.89)
Immunosuppressive drugsa 6 (11.3)
dsDNA: double stranded DNA; NSAID: non-steroidal anti-inﬂammatory drug.
a Methotrexate, azathioprine, cyclophosphamide, cyclosporine A or
mycophenolatemophetil.
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(45.46) pg/ml) and TNFa (39.24 (116.03) pg/ml) in SLE patients
were elevated with respect to controls (IFNa: 5.54 (2.80); TNFa:
19.84 (71.91); pg/ml) and positively correlated in SLE patients
(r = 0.291, p = 0.04, Spearman’s rank correlation test). Thus,
patients were classiﬁed in IFNa-low and IFNa-high using the
percentile 80 obtained in healthy controls (n = 45) as cut off
(P80 = 29.25 pg/ml). In agreement with previous results [20,21],
antimalarial treated SLE patients showed strikingly lower levels
of TNFa (81.14%) compared to those without such treatment
(86.88 (107.03) vs 16.39 (60.94) pg/ml)). STAT4 gene expression
tends to decrease in patients under antimalarial treatment (64.90
(52.46) vs 57.24 (69.49), n.s.), but, interestingly, the lowest levels,
compared to the rest of patients, were observed in IFNa-high
antimalarial-treated patients (68.74 (56.05) vs 27.72 (65.95),
p = 0.02), whereas this treatment seems to be ineffective in
reducing STAT4 expression in patients with low IFNa serum levels
(Fig. 4). This reduction of STAT4 levels was not observed in patients
under glucocorticoid or immunosuppressive treatments. More-
over, presence of these drugs in combination with antimalarial
therapy did not inﬂuence STAT4 levels (Supplementary Table 2).
5. Discussion
During the last few years, the existence of a cross-regulation
between type I IFNs and TNFa has been proposed, so that these
cytokines can be regarded as opposite vectors in the immune
response, remaining balanced under homeostatic conditions but
losing equilibrium in speciﬁc pathological states, such as autoim-
munity. In fact, several in vitro and in vivo studies showed an
inhibitory effect of TNFa on type I IFNs, whereas a reciprocal
suppressive effect of IFNa/b on TNFa production has also been
suggested. Nevertheless, this counterbalance is controversial in
several autoinﬂammatory diseases, in which both cytokines may
exert a pathological effect.
In this work we observed that IFNa treatment increases TNFa
secretion and the number of TNFa-producer cells after in vitro
monocyte stimulation with LPS. Although several works reported
a suppressive effect of type I IFNs in the TNFa production [30–
34], other cellular studies suggested that this proposed inhibitory
effect may be dependent on both cell type and inﬂammatory con-
ditions. In this sense, it has been observed that IFNb diminishes
in vitro TNFa production in T-cell contact-activated monocytes,
while the same cytokine enhances TNFa production in LPS-acti-
vated monocytes [35]. Moreover, previous exposure to low doses
of type I IFNs enhances subsequent response to proinﬂammatory
cytokines such as TNFa by several immune cells [36].
These data are in line with the elevated and directly correlated
serum levels of TNFa and IFNa detected in SLE patients that were
previously described in a large group [23,24]. Other authors ob-
served that the -308ATNFa allele, associated with an increased
production of this cytokine, was positively correlated with higher
IFNa serum levels in untreated patients of dermatomyositis at dis-
ease onset, suggesting that the relationship between both cyto-
kines could be inﬂuenced by the treatment or the disease
progression [37]. It has also been described that anti-IFNa mono-
clonal antibody treatment down-modulated TNFa mRNA expres-
sion in peripheral blood and skin lesions in SLE patients [38].
Taking into consideration our results and the published cellular,
experimental, and human data, it seems clear that IFNa and TNFa
have pleiotropic effects that depend on the time, dosage and cell
type, so cross-regulation between both cytokines may occur in
physiological conditions, where every cytokine controls another,
but is certainly not a universal principle in pathological conditions,
such as autoimmunity or inﬂammation [39]. In fact, if cross-
regulation was effective, type I IFN response program might
Fig. 1. Induction of TNFa secretion by IFNa in monocytes and T cells. Isolated monocytes (a) and T cells (b) were incubated at different times with IFNa alone or at the same
time of LPS or PHA stimulation and supernatants from such cultures were collected for the quantiﬁcation of TNFa production by ELISA. Points represent the median and
interquartile range of TNFa (pg/ml) obtained in ﬁve independent experiments performed with different blood donors. Intracellular TNFa expression in IFNa- treated
monocytes (c). Dot-plots represent the percentage of TNFa-producer CD14+ cells after incubation for 24 h with IFNa alone or in combination with LPS. Analysis of the
intracellular TNFa accumulation was performed by ﬂow cytometry. A representative experiment was shown.
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hamper the elevated TNFa production. However, it is well known
that both IFNa and TNFa are over-expressed in many patients with
SLE and other autoimmune diseases, sometimes associated with
disease activity [40,41]. In such patients, the presence of nucleic
acid-containing immune-complexes induces plasmacytoid DCs,
and probably other cell types, to produce IFNa [42] after stimula-
tion across TLR-7/9 [9,43]. Similarly, immune-complexes can in-
duce TNFa production [44]. In addition, TNFa may directly
stimulate the interferon pathway by inducing IFNb [45].
Antimalarial agents, which have long been used in the treat-
ment of rheumatic diseases, are currently prescribed to SLE pa-
tients and they have been associated with a ﬂare reduction and
severe disease exacerbations [16,46]. Despite some uncertainty
regarding the exact mechanisms underlying their antiinﬂamma-
tory effects, in vitro studies showed that chloroquine interferes
with the expression of TNFa and other proinﬂammatory cytokines
[17,19], probably by affecting the cellular lysosomal acidiﬁcation
[18]. Also, studies in SLE patients showed that antimalarial treat-
ment reduces serum levels of TNFa [20,21], thus suggesting that
cytokine inhibition may be involved in a beneﬁcial outcome.
Accordingly, our results conﬁrmed that chloroquine treatment
inhibits the in vitro production of TNFa by healthy LPS-stimulated
monocytes, but, in addition, we demonstrated this inhibitory effect
even when TNFa induction is enhanced by IFNa, an expected situ-
ation in most SLE patients.
Interestingly, lysosomal acidiﬁcation, an effect of antimalarial
agents, is necessary for the TLR activation, so these drugs have
been described as antagonists of the TLR7/9 stimulation [47].
Therefore, hydroxychloroquine blocks TLR-mediated activation of
pDC in vitro, as shown by inhibition of IFNa synthesis, either after
induction by immune-complexes [9] or upon stimulation with
TLR9 agonists [48,49]. Recently, it has been observed that the sig-
niﬁcant clinical improvement in SLE patients after hydroxychloro-
quine therapy correlated with reductions in IFNa levels [50].
Fig. 2. Effect of the chloroquine treatment on the IFNa-induced TNFa production. Monocytes cultured for 24 h with IFNa, alone or in combination with LPS, were collected for
ﬂow cytometric quantiﬁcation of intracellular TNFa while supernatants from such cultures were used for TNFa quantiﬁcation by ELISA. Bars represent mean and SD of TNFa
levels in the supernatants of 6 healthy blood donors. Statistical signiﬁcance between presence/absence of chloroquine in each culture was assessed by Wilcoxon test for
paired data (***p < 0.0001) (a). Histograms represent the intracellular TNFa expression in a representative donor (shaded) with the respective isotype matched control
antibody (black dotted line). Numbers indicate the median ﬂuorescence intensity of TNFa staining with the matched irrelevant control value subtracted (DMFI) and
percentage of positive cells (% ve) (b).
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Furthermore, treatment with hydroxychloroquine was associated
with an impaired ability of pDCs from subjects with SLE to produce
IFNa and TNFa upon stimulation with TLR7/9 agonists [51].
On the other hand, in agreement with the functional relation-
ship between STAT4 and type I IFN receptor signaling, our results
showed an upregulation of STAT4 protein expression after IFNa
treatment in LPS-stimulated monocytes, in parallel to the increase
in the production of TNFa. Since the binding of IFNa to its receptor
leads to STAT4 phosphorylation and the subsequent transcription
of several IFNa-response proinﬂammatory molecules in humans
[10,11], our results might suggest that the IFNa-induced TNFa
secretion by monocytes could be mediated by STAT4. In accor-
dance with this hypothesis, our in vitro results revealed, for the
ﬁrst time, that chloroquine treatment was able to reduce STAT4
levels in IFNa and LPS-stimulated monocytes. Actually, IFNa is
an inductor of the differentiation and maturation of monocytes
into DCs, and it has been suggested that STAT4 expression could
reﬂect a signal transduction pathway in response to IFNa in this
monocyte cellular progression [52].
Finally, to conﬁrm our in vitro results, we analyzed the effect of
the antimalarial therapy on STAT4 gene expression and TNFa ser-
um levels in SLE patients. As expected, antimalarial treated SLE pa-
tients showed strikingly lower levels of TNFa than those without
such treatment, but, surprisingly, no signiﬁcant differences were
observed in STAT4 expression. We found, however, that patients
under antimalarial treatment and high IFNa levels, showed dimin-
ished STAT4 expression, whereas this therapy seemed to be inef-
fective in reducing STAT4 in patients with low IFNa levels. Thus,
STAT4 expression in patients treated with antimalarials depends
on the circulating amounts of IFNa, those patients with high levels
of IFNa presenting the lowest expression. A possible explanation
for the reduced antimalarial-mediated down regulation of STAT4
in the IFNa low group of patients should be related to the presence
of certain allelic variants of STAT4 known to constitute a risk factor
for SLE and that has been associated with low IFNa serum activity
but greater sensitivity to type I IFN signaling in SLE patients [53].
On the other hand, SLE patients with the STAT4 non-risk genotype
displayed the commonly observed high IFNa production, which
seems to be required for STAT4 downregulation after antimalarial
treatment. Therefore, this therapy might be more effective in pa-
tients carriers of the wild STAT4 genotype presenting high IFNa
levels.
Moreover, gene polymorphisms at the interferon regulatory fac-
tor 5 (IRF5), a major mediator of TLR-triggered expression of type I
IFN [53] and other proinﬂammatory cytokines, including TNFa
[54], act additively with STAT4 genotype to increase the risk for
SLE [13,55]. This fact could be explained by the functional link
between both molecules, since the risk allele of STAT4 determines
a higher frequency of anti-dsDNA antibodies in SLE patients, allow-
ing a continued type I IFN stimulation of the STAT4-dependent
autoimmune response [13,53].
All these data suggest that antimalarial treatment could be able
to reduce STAT4 expression by blocking the interaction between
TLR and immune-complexes, thus avoiding the IRF5 action and
interfering with IFNa induction. However, in SLE patients with
low IFNa production, a feature associated with a low presence of
autoantibodies [24] and TNFa [23,56], antimalarial therapy could
Fig. 3. Effect of IFNa and chloroquine on the STAT4 expression in stimulated monocytes. Cells from healthy donors cultured for 24 h in the presence or absence of LPS, IFNa
and chloroquine were collected and intracellularly stained for STAT4-FITC expression by ﬂow cytometry. Histograms represent the intracellular STAT4 expression in a donor
as example (shaded) with the respective isotype matched control antibody (black dotted line). Numbers indicate the median ﬂuorescence intensity of STAT4 staining with the
matched irrelevant control value subtracted (DMFI) from one representative experiment (n = 6).
Fig. 4. STAT4 gene expression in SLE patients with and without antimalarial
treatment and classiﬁed by their IFNa serum levels. SLE patients were classiﬁed as
IFNa-low or IFNa-high using the percentile 80 in healthy controls as cut off. Scatter
plots represent STAT4 mRNA relative units from peripheral blood cells of SLE
patients with or without antimalarials. Horizontal bars show the median. Statistical
signiﬁcance was assessed by Mann–Whitney U test (*p < 0.05).
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be ineffective in reducing STAT4 expression, thus suggesting the
use of IFNa as a possible biomarker of the clinical response to
antimalarials.
6. Conclusions
The present study showed an enhanced in vitro effect of IFNa on
the TNFa induction in LPS-activated monocytes from healthy indi-
viduals, which could explain the positive correlation observed in
SLE patients between both cytokines. This IFNa upregulatory effect
was also observed in the levels of STAT4, being both TNFa and
STAT4 inhibited when chloroquine was added during stimulation
of healthy monocytes. However, results obtained in SLE patients
suggest that STAT4 expression is not always decreased during anti-
malarial treatment, but depends on the circulating levels of IFNa,
which could contribute to an immune activation situation result-
ing in STAT4 and TNFa induction. Therefore, antimalarial therapy
may be especially beneﬁcial to improve SLE pathogenesis in
patients with an overactive IFNa pathway, which thus can be
blocked.
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